Biotop-report 2011
Yüklə 0,8 Mb. Pdf görüntüsü
|
- Bu səhifədəki naviqasiya:
- Close links between science and industry
- Dr. Andreas Baltrusch
- Address
13 B i o T O P i c s 4 2 _ B i o T O P R e p o r t 2 0 1 1
Based on early initiatives to promote networking between research groups in the field of regenerative medicine, the “Regen- erative Medicine Initiative Berlin” (RMIB) was founded in 2003. Initially focused primarily on science, the network opened out to the corporate sector in 2007 and has concentrated since then on networking between scientists and industry as well as between companies in Berlin and Brandenburg. Today the RMIB is supported by the BCRT and BioTOP. Its activities focus on the continued extension of the regional interaction and information network between science and industry. That com- prises joint working groups between scientists and users, com- munication structures between the players in regenerative medi- cine, and between them and adjacent fields as well as regional political institutions, and location marketing. In terms of content, cooperation is guided by the themes of the regional working groups, i. e. the research areas and applica- tions of regional companies, the BCRT and other regional research facilities. Within these thematic areas, companies and working groups establish joint projects using the RMIB communication platform and implement them with funding from suitable – often regional – funding programmes. The RMIB’s most important communication tool is the “Treffpunkt Regenerative Medizin” as a discussion and event platform covering current developments. In addition, the RMIB organises other spe- cialised and interdisciplinary meetings and conferences. In several working groups researchers and companies share their experienc- es regarding regulatory issues or reimbursement strategies. Topping ceremony of the Bio medi zin technikum II at the Center for Biomate- rial Development in Teltow in December 2010. The picture shows Minister Martina Münch (2nd from left), Helmholtz-Zentrum Geesthacht CEO Michael Ganss, Prof. Dr. Andreas Lendlein, director of the HZG Centre for Biomaterial Development and Vice Director of the BCRT.
CEO · co.don AG Regenerative Therapies Instead of Prostheses » More than 4,000 patients with joint and spinal disc problems have already been treated with our autologous cartilage transplants – and the success quota is very high. We are currently conducting two clinical trials which are the precondition for the approval and hence also the marketing of tissue engineering products under new legislation in the European Union. They will enable us to gain a far larger mar- ket share with our autologous cartilage cell products whose use is already refunded by the health insurers in Germany. 14 B i o T O P i c s 4 2 _ B i o T O P R e p o r t 2 0 1 1 Epigenomics AG Epigenomics is a molecular diagnostics company developing and commercializ- ing a pipeline of proprietary products for cancer. Epigenomics’ products enable doctors to diagnose cancer earlier and more accurately, leading to improved outcomes for patients. Epigenom- ics’ lead product, Epi proColon ® , is a
blood-based test for the early detection of colorectal cancer, which is currently marketed in Europe and is in develop- ment for the U.S.A. The product portfolio further includes Epi proLung ® , a confir- matory test aiding in the diagnosis of lung cancer that is marketed in Europe, and further products in development for colorectal, lung and prostate cancer. Epigenomics technology and products have been validated through multiple partnerships with leading global diag- nostic companies including Abbott, QIAGEN, Sysmex, and Quest Diagnostics. Epigenomics is an international compa- ny with operations in Berlin, Germany, and Seattle, WA, U.S.A. For further information please visit www.epigenomics.com Address Epigenomics AG Kleine Präsidentenstraße 1 10178 Berlin · Germany Phone +49 30 243450 Fax
+49 30 24345555 contact@epigenomics.com www.epigenomics.com co.don
co.don ® AG is a public biopharmaceu- tical company, founded in November 1993, since 2001 listed on Frankfurt stock exchange. co.don ® AG manu- factures cell-based tissue engineering therapeutics of the highest purity and to the highest quality standards. Its prod- ucts represent a revolutionary process in the biological replacement of damaged articular cartilage, invertebral disc and bone by building up strictly autologous tissue without the involvement of any external carrier materials or additives. The application of the products may be minimally invasive or arthroscopic and so surgery and rehabilitation times significantly reduced for doctor and patient. Because no external materials are used, the risks of rejection, inflam- mation and infection are very slight. co.don ®
with DIN EN ISO 9001:2008. Further- more, production, quality control and quality assurance have been certified in accordance with European Guidelines for Good Manufacturing Practice (EU-GMP) since 1997. In 1997 co.don ® AG was
the first biopharmaceutical company in Europe to be granted a permit for the manufacture of autologous chondrocyte and osteoblast transplants under sec- tion 13 of the German Drugs Law (AMG). co.don
® AG‘s technological, produc- tion and regulatory expertise makes the company a first mover in the market for biological cartilage and bone replace- ment and a provider of highly effective, safe treatment options between pain therapy and endoprothetics. Address co.don AG Warthestraße21 14513 Teltow · Germany Contact Matthias Meißner, M.A. Head Corporate Communications/IR/PR Phone +49 3328 4346 0 Fax +49 3328 4346 43 info@codon.de · www.codon.de Yüklə 0,8 Mb. Dostları ilə paylaş:
|